Iterum Therapeutics (ITRM) Q2 2024 earnings summary

Executive summary

• Rights offering closed in August 2024, raising $5.8 million net to support ongoing business and strategic initiatives, including maximizing the value of sulopenem.

• NDA for oral sulopenem resubmitted in April 2024 for uUTIs in adult women; FDA Advisory Committee meeting scheduled for September 9, 2024, and PDUFA action date set for October 25, 2024.

• Positive topline data from pivotal Phase 3 REASSURE trial for uUTI in adult women.

• Expanded intellectual property portfolio with new patent allowances in the U.S. and Canada, and pending applications in other territories, extending protection to 2039–2041.

• Substantial doubt exists about the ability to continue as a going concern due to limited cash and upcoming debt maturities.

Financial highlights

• Operating expenses for Q2 2024 were $4 million, down from $10.8 million in Q2 2023, mainly due to lower R&D costs after completion of the REASSURE trial.

• Net loss (GAAP) for Q2 2024 was $5 million, compared to $12.2 million in Q2 2023; non-GAAP net loss was $3.8 million, down from $10 million year-over-year.

• Cash, cash equivalents, and short-term investments totaled $11.7 million as of June 30, 2024, with an additional $5.8 million from the rights offering.

• Total assets were $14.2 million and total liabilities $25.1 million as of June 30, 2024, with a shareholders' deficit of $10.9 million.

• Net loss per share for Q2 2024 was $0.30, improved from $0.95 in Q2 2023.

Outlook and guidance

• Current cash position, including rights offering proceeds, is expected to fund operations into 2025 and through the anticipated FDA decision period.

• Management is seeking additional funding through equity or debt offerings and is evaluating strategic alternatives, including asset sales or licensing.

• Plans to seek shareholder approval to disapply preemption rights, enabling more flexible and timely capital raises.

• The outcome of the FDA Advisory Committee and subsequent NDA decision for oral sulopenem will be critical to future prospects.